Concepts (287)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nanoparticles | 15 | 2020 | 318 | 3.160 |
Why?
|
| Polyglycolic Acid | 14 | 2015 | 37 | 2.790 |
Why?
|
| Lactic Acid | 14 | 2015 | 95 | 2.670 |
Why?
|
| Drug Carriers | 13 | 2015 | 125 | 2.540 |
Why?
|
| Drug Delivery Systems | 14 | 2020 | 202 | 2.290 |
Why?
|
| Polymers | 9 | 2015 | 121 | 1.900 |
Why?
|
| Radiation-Protective Agents | 5 | 2016 | 14 | 1.790 |
Why?
|
| Drug Compounding | 19 | 2024 | 76 | 1.630 |
Why?
|
| Amifostine | 6 | 2008 | 9 | 1.590 |
Why?
|
| Chromones | 8 | 2023 | 54 | 1.550 |
Why?
|
| RNA, Small Interfering | 5 | 2017 | 409 | 1.400 |
Why?
|
| Particle Size | 18 | 2017 | 215 | 1.250 |
Why?
|
| Polyglactin 910 | 5 | 2015 | 9 | 1.130 |
Why?
|
| Drug Stability | 15 | 2024 | 116 | 1.110 |
Why?
|
| Excipients | 7 | 2022 | 22 | 1.070 |
Why?
|
| Chitosan | 4 | 2010 | 36 | 1.070 |
Why?
|
| Administration, Oral | 16 | 2024 | 224 | 1.010 |
Why?
|
| Surface-Active Agents | 4 | 2014 | 41 | 1.000 |
Why?
|
| Chemistry, Pharmaceutical | 9 | 2015 | 71 | 1.000 |
Why?
|
| Gene Silencing | 3 | 2017 | 151 | 0.970 |
Why?
|
| Capsules | 10 | 2008 | 25 | 0.970 |
Why?
|
| Suspensions | 12 | 2024 | 46 | 0.830 |
Why?
|
| Chromatography, High Pressure Liquid | 13 | 2024 | 421 | 0.740 |
Why?
|
| Biocompatible Materials | 4 | 2011 | 76 | 0.720 |
Why?
|
| Liposomes | 6 | 2020 | 118 | 0.720 |
Why?
|
| Technology, Pharmaceutical | 5 | 2015 | 27 | 0.700 |
Why?
|
| Antineoplastic Agents | 5 | 2017 | 803 | 0.680 |
Why?
|
| Polyethylene Glycols | 4 | 2020 | 84 | 0.680 |
Why?
|
| Insulin | 2 | 2015 | 236 | 0.670 |
Why?
|
| Microscopy, Electron, Scanning | 10 | 2015 | 142 | 0.650 |
Why?
|
| Pentamidine | 4 | 2004 | 9 | 0.650 |
Why?
|
| Fenretinide | 2 | 2015 | 8 | 0.640 |
Why?
|
| Solubility | 11 | 2015 | 118 | 0.610 |
Why?
|
| Osteosarcoma | 1 | 2017 | 26 | 0.590 |
Why?
|
| Chromans | 1 | 2016 | 15 | 0.580 |
Why?
|
| Bone Neoplasms | 1 | 2017 | 45 | 0.580 |
Why?
|
| Clindamycin | 1 | 2016 | 13 | 0.570 |
Why?
|
| Nanostructures | 4 | 2013 | 134 | 0.560 |
Why?
|
| Vitamin E | 1 | 2016 | 61 | 0.560 |
Why?
|
| Squalene | 1 | 2015 | 3 | 0.530 |
Why?
|
| Mebendazole | 1 | 2015 | 4 | 0.530 |
Why?
|
| Tubulin Modulators | 1 | 2015 | 18 | 0.520 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2017 | 213 | 0.510 |
Why?
|
| Drug Storage | 7 | 2023 | 27 | 0.490 |
Why?
|
| Fatty Acids | 1 | 2015 | 127 | 0.480 |
Why?
|
| Fluorescence | 2 | 2016 | 121 | 0.480 |
Why?
|
| Coumarins | 2 | 2011 | 38 | 0.480 |
Why?
|
| Micelles | 1 | 2014 | 32 | 0.480 |
Why?
|
| Molecular Imaging | 1 | 2014 | 30 | 0.470 |
Why?
|
| Delayed-Action Preparations | 5 | 2008 | 60 | 0.470 |
Why?
|
| Buprenorphine | 2 | 2007 | 21 | 0.460 |
Why?
|
| Amino Acid Transport Systems, Neutral | 1 | 2013 | 4 | 0.460 |
Why?
|
| Hypoglycemic Agents | 1 | 2015 | 160 | 0.460 |
Why?
|
| Nanocapsules | 2 | 2010 | 17 | 0.450 |
Why?
|
| Skin Absorption | 1 | 2013 | 15 | 0.450 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 352 | 0.450 |
Why?
|
| Lipids | 3 | 2013 | 235 | 0.440 |
Why?
|
| Calorimetry, Differential Scanning | 5 | 2015 | 30 | 0.430 |
Why?
|
| Mice | 14 | 2016 | 5913 | 0.430 |
Why?
|
| Copper | 1 | 2013 | 105 | 0.430 |
Why?
|
| Propranolol | 2 | 2010 | 18 | 0.420 |
Why?
|
| Vaccines | 1 | 2013 | 55 | 0.420 |
Why?
|
| Liver | 2 | 2012 | 479 | 0.410 |
Why?
|
| Freeze Drying | 1 | 2011 | 27 | 0.410 |
Why?
|
| RNA Stability | 1 | 2011 | 26 | 0.410 |
Why?
|
| Sulfhydryl Compounds | 1 | 2011 | 47 | 0.400 |
Why?
|
| Biodegradation, Environmental | 6 | 2006 | 80 | 0.390 |
Why?
|
| Solvents | 4 | 2008 | 99 | 0.380 |
Why?
|
| Emulsions | 5 | 2016 | 33 | 0.370 |
Why?
|
| RNA Interference | 1 | 2011 | 243 | 0.370 |
Why?
|
| Metal Nanoparticles | 1 | 2013 | 183 | 0.370 |
Why?
|
| Cell Line, Tumor | 8 | 2020 | 2231 | 0.370 |
Why?
|
| Tablets, Enteric-Coated | 1 | 2010 | 1 | 0.360 |
Why?
|
| Genetic Vectors | 1 | 2010 | 158 | 0.360 |
Why?
|
| Cellulose | 1 | 2010 | 14 | 0.360 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 485 | 0.350 |
Why?
|
| Antifungal Agents | 3 | 2000 | 148 | 0.350 |
Why?
|
| Animals | 17 | 2020 | 15081 | 0.350 |
Why?
|
| Serum Albumin, Bovine | 3 | 2013 | 51 | 0.340 |
Why?
|
| Mercaptoethylamines | 1 | 2008 | 1 | 0.330 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2008 | 121 | 0.320 |
Why?
|
| Apolipoproteins E | 3 | 2016 | 129 | 0.320 |
Why?
|
| Glycolates | 2 | 2007 | 6 | 0.320 |
Why?
|
| Indomethacin | 1 | 2008 | 28 | 0.320 |
Why?
|
| Breast Neoplasms | 3 | 2020 | 1502 | 0.320 |
Why?
|
| Cell Survival | 4 | 2017 | 864 | 0.310 |
Why?
|
| Polyvinyl Alcohol | 3 | 2002 | 5 | 0.300 |
Why?
|
| Transfection | 4 | 2013 | 523 | 0.300 |
Why?
|
| Hepacivirus | 3 | 2012 | 62 | 0.300 |
Why?
|
| DNA | 1 | 2010 | 574 | 0.300 |
Why?
|
| Humans | 23 | 2023 | 37093 | 0.290 |
Why?
|
| Zidovudine | 2 | 1996 | 34 | 0.280 |
Why?
|
| Spectrophotometry, Ultraviolet | 3 | 2015 | 98 | 0.280 |
Why?
|
| Enkephalin, Leucine | 1 | 2006 | 5 | 0.270 |
Why?
|
| Permeability | 3 | 2015 | 67 | 0.270 |
Why?
|
| Diabetic Retinopathy | 2 | 2016 | 68 | 0.260 |
Why?
|
| Hydrogels | 2 | 2002 | 37 | 0.260 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2005 | 68 | 0.250 |
Why?
|
| Viscosity | 4 | 2017 | 38 | 0.250 |
Why?
|
| Hydrogen-Ion Concentration | 4 | 2020 | 364 | 0.240 |
Why?
|
| Clonidine | 1 | 2024 | 52 | 0.240 |
Why?
|
| Surface Properties | 3 | 2010 | 130 | 0.240 |
Why?
|
| Lactose | 2 | 2016 | 14 | 0.230 |
Why?
|
| Azathioprine | 1 | 2023 | 5 | 0.230 |
Why?
|
| Mice, Inbred BALB C | 4 | 2015 | 661 | 0.230 |
Why?
|
| Tablets | 2 | 2009 | 9 | 0.220 |
Why?
|
| Malaria, Falciparum | 2 | 2015 | 90 | 0.220 |
Why?
|
| Kinetics | 4 | 2015 | 708 | 0.220 |
Why?
|
| Plasmodium falciparum | 2 | 2015 | 135 | 0.210 |
Why?
|
| Amitriptyline | 1 | 2022 | 9 | 0.210 |
Why?
|
| Temperature | 2 | 2016 | 286 | 0.210 |
Why?
|
| Retina | 2 | 2016 | 280 | 0.200 |
Why?
|
| Peptide Fragments | 2 | 2016 | 308 | 0.200 |
Why?
|
| Receptor, erbB-2 | 2 | 2020 | 133 | 0.200 |
Why?
|
| Protamines | 2 | 2011 | 18 | 0.200 |
Why?
|
| Metronidazole | 1 | 2021 | 13 | 0.190 |
Why?
|
| Administration, Inhalation | 2 | 2015 | 80 | 0.190 |
Why?
|
| Spectrometry, Fluorescence | 2 | 2014 | 208 | 0.190 |
Why?
|
| Miconazole | 1 | 2000 | 4 | 0.190 |
Why?
|
| Methylene Chloride | 3 | 2008 | 6 | 0.190 |
Why?
|
| Hydrocortisone | 1 | 2021 | 78 | 0.190 |
Why?
|
| Gelatin | 1 | 2020 | 15 | 0.190 |
Why?
|
| Allopurinol | 1 | 2020 | 12 | 0.190 |
Why?
|
| Hepatitis C | 2 | 2012 | 125 | 0.190 |
Why?
|
| Uric Acid | 1 | 2020 | 26 | 0.180 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2020 | 44 | 0.180 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 2000 | 21 | 0.180 |
Why?
|
| Doxorubicin | 1 | 2020 | 84 | 0.180 |
Why?
|
| Amlodipine | 1 | 2019 | 21 | 0.180 |
Why?
|
| Antihypertensive Agents | 2 | 2019 | 284 | 0.170 |
Why?
|
| Flow Cytometry | 2 | 2011 | 399 | 0.170 |
Why?
|
| Carbon | 1 | 2020 | 105 | 0.170 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1999 | 4 | 0.170 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2019 | 5 | 0.170 |
Why?
|
| Naltrexone | 1 | 2019 | 38 | 0.170 |
Why?
|
| Caco-2 Cells | 2 | 2015 | 52 | 0.160 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2016 | 94 | 0.160 |
Why?
|
| Nebulizers and Vaporizers | 2 | 2008 | 19 | 0.160 |
Why?
|
| Biological Availability | 2 | 2008 | 88 | 0.160 |
Why?
|
| Sulfadiazine | 1 | 2017 | 4 | 0.150 |
Why?
|
| Trimethoprim | 1 | 2017 | 6 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2005 | 643 | 0.150 |
Why?
|
| Acute Radiation Syndrome | 1 | 2016 | 2 | 0.150 |
Why?
|
| Tissue Distribution | 2 | 2010 | 207 | 0.150 |
Why?
|
| Spironolactone | 1 | 2017 | 39 | 0.140 |
Why?
|
| Aptamers, Nucleotide | 1 | 2017 | 31 | 0.140 |
Why?
|
| Blood Glucose | 2 | 2016 | 353 | 0.140 |
Why?
|
| Opioid-Related Disorders | 1 | 1999 | 125 | 0.140 |
Why?
|
| Retinal Neovascularization | 1 | 2016 | 10 | 0.140 |
Why?
|
| Neoplasms | 1 | 2007 | 1103 | 0.140 |
Why?
|
| Molecular Weight | 2 | 2009 | 167 | 0.140 |
Why?
|
| Leucine | 1 | 2016 | 29 | 0.140 |
Why?
|
| Receptors, LDL | 1 | 2016 | 30 | 0.140 |
Why?
|
| Tumor Cells, Cultured | 1 | 2017 | 502 | 0.140 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2016 | 59 | 0.140 |
Why?
|
| Naphthalenes | 1 | 2016 | 38 | 0.130 |
Why?
|
| Water | 1 | 1998 | 296 | 0.130 |
Why?
|
| Poloxamer | 1 | 2015 | 9 | 0.130 |
Why?
|
| Transition Temperature | 1 | 2015 | 8 | 0.130 |
Why?
|
| Microspheres | 3 | 2001 | 49 | 0.130 |
Why?
|
| Hydrogen Sulfide | 1 | 2016 | 39 | 0.130 |
Why?
|
| Intestinal Absorption | 1 | 2015 | 20 | 0.130 |
Why?
|
| Malaria Vaccines | 1 | 2015 | 21 | 0.130 |
Why?
|
| Esters | 1 | 2015 | 28 | 0.130 |
Why?
|
| Fatty Acids, Monounsaturated | 2 | 2012 | 20 | 0.130 |
Why?
|
| Quaternary Ammonium Compounds | 2 | 2012 | 34 | 0.130 |
Why?
|
| Povidone | 1 | 2014 | 5 | 0.130 |
Why?
|
| Fluorescent Dyes | 1 | 2016 | 181 | 0.130 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 194 | 0.120 |
Why?
|
| Intestinal Mucosa | 1 | 2015 | 122 | 0.120 |
Why?
|
| Artemisinins | 1 | 2014 | 20 | 0.120 |
Why?
|
| Solutions | 1 | 2014 | 62 | 0.120 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 204 | 0.120 |
Why?
|
| Mass Spectrometry | 1 | 2015 | 260 | 0.120 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 515 | 0.120 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2014 | 146 | 0.120 |
Why?
|
| Cholesterol | 2 | 2012 | 205 | 0.110 |
Why?
|
| Antimalarials | 1 | 2014 | 55 | 0.110 |
Why?
|
| Time Factors | 2 | 2011 | 1742 | 0.110 |
Why?
|
| Protozoan Proteins | 1 | 2015 | 182 | 0.110 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2013 | 22 | 0.110 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2014 | 132 | 0.110 |
Why?
|
| Plasmids | 2 | 2013 | 246 | 0.110 |
Why?
|
| Administration, Cutaneous | 1 | 2013 | 43 | 0.110 |
Why?
|
| Male | 6 | 2016 | 20025 | 0.110 |
Why?
|
| Hela Cells | 1 | 2014 | 366 | 0.110 |
Why?
|
| Virus Replication | 2 | 2012 | 278 | 0.110 |
Why?
|
| Mutation | 1 | 2017 | 1095 | 0.110 |
Why?
|
| Erythrocytes | 1 | 2013 | 111 | 0.100 |
Why?
|
| Sonication | 1 | 2011 | 16 | 0.100 |
Why?
|
| Extracellular Matrix | 1 | 2012 | 115 | 0.100 |
Why?
|
| Interferon-alpha | 1 | 2011 | 43 | 0.100 |
Why?
|
| Drug Resistance, Viral | 1 | 2011 | 63 | 0.100 |
Why?
|
| Hepatocytes | 1 | 2011 | 75 | 0.100 |
Why?
|
| Glucose | 1 | 2012 | 230 | 0.100 |
Why?
|
| Cell Culture Techniques | 1 | 2011 | 142 | 0.100 |
Why?
|
| Nucleic Acid Conformation | 1 | 2011 | 146 | 0.100 |
Why?
|
| Microscopy, Fluorescence | 1 | 2011 | 252 | 0.090 |
Why?
|
| Pressure | 1 | 2010 | 43 | 0.090 |
Why?
|
| RNA, Viral | 1 | 2012 | 301 | 0.090 |
Why?
|
| Gene Transfer Techniques | 1 | 2010 | 47 | 0.090 |
Why?
|
| Eye | 1 | 2011 | 71 | 0.090 |
Why?
|
| Nanotechnology | 1 | 2011 | 153 | 0.090 |
Why?
|
| Antiviral Agents | 1 | 2011 | 157 | 0.090 |
Why?
|
| Peptides | 1 | 2012 | 320 | 0.090 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 127 | 0.090 |
Why?
|
| Thiazoles | 1 | 2010 | 74 | 0.090 |
Why?
|
| Biological Transport | 1 | 2010 | 185 | 0.090 |
Why?
|
| Endothelial Cells | 1 | 2012 | 308 | 0.090 |
Why?
|
| Sodium Bicarbonate | 1 | 2009 | 8 | 0.080 |
Why?
|
| Citric Acid | 1 | 2009 | 9 | 0.080 |
Why?
|
| Jejunum | 1 | 2008 | 8 | 0.080 |
Why?
|
| Bone Marrow | 1 | 2008 | 37 | 0.080 |
Why?
|
| Polyesters | 2 | 1999 | 25 | 0.080 |
Why?
|
| Administration, Rectal | 1 | 2008 | 18 | 0.080 |
Why?
|
| Injections, Subcutaneous | 1 | 2008 | 33 | 0.080 |
Why?
|
| Cytoprotection | 1 | 2008 | 36 | 0.080 |
Why?
|
| Child | 3 | 2021 | 3131 | 0.080 |
Why?
|
| Cations | 1 | 2008 | 45 | 0.080 |
Why?
|
| Phosphatidylcholines | 1 | 2008 | 47 | 0.080 |
Why?
|
| Polysorbates | 1 | 2007 | 10 | 0.080 |
Why?
|
| Survival Rate | 1 | 2008 | 311 | 0.080 |
Why?
|
| Stem Cells | 1 | 2008 | 141 | 0.070 |
Why?
|
| Gels | 1 | 2007 | 42 | 0.070 |
Why?
|
| Patents as Topic | 1 | 2007 | 14 | 0.070 |
Why?
|
| Materials Testing | 1 | 2006 | 69 | 0.070 |
Why?
|
| Drug Design | 1 | 2007 | 162 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2011 | 1198 | 0.060 |
Why?
|
| Safety | 1 | 2005 | 48 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 1039 | 0.060 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2005 | 43 | 0.060 |
Why?
|
| Thermodynamics | 1 | 2006 | 216 | 0.060 |
Why?
|
| Bone Marrow Cells | 1 | 2005 | 81 | 0.060 |
Why?
|
| Biotransformation | 1 | 2004 | 67 | 0.060 |
Why?
|
| Blotting, Western | 2 | 2016 | 859 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2005 | 212 | 0.060 |
Why?
|
| Cattle | 1 | 2005 | 477 | 0.060 |
Why?
|
| Female | 4 | 2020 | 20969 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2016 | 1609 | 0.050 |
Why?
|
| Administration, Intravaginal | 1 | 2000 | 8 | 0.050 |
Why?
|
| Freezing | 1 | 2000 | 16 | 0.050 |
Why?
|
| Absorbable Implants | 1 | 1999 | 3 | 0.040 |
Why?
|
| Pneumocystis | 1 | 1999 | 1 | 0.040 |
Why?
|
| Acetone | 1 | 1999 | 7 | 0.040 |
Why?
|
| Dimethyl Sulfoxide | 1 | 1999 | 16 | 0.040 |
Why?
|
| Methanol | 1 | 1999 | 18 | 0.040 |
Why?
|
| Acetates | 1 | 1999 | 21 | 0.040 |
Why?
|
| Metoprolol | 1 | 1998 | 3 | 0.040 |
Why?
|
| Diltiazem | 1 | 1998 | 5 | 0.040 |
Why?
|
| Captopril | 1 | 1998 | 8 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 1998 | 54 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1998 | 52 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 1998 | 56 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2017 | 98 | 0.040 |
Why?
|
| Ethanol | 1 | 1999 | 192 | 0.040 |
Why?
|
| Leukostasis | 1 | 2016 | 4 | 0.040 |
Why?
|
| Blood-Retinal Barrier | 1 | 2016 | 8 | 0.040 |
Why?
|
| Fluorescein Angiography | 1 | 2016 | 8 | 0.040 |
Why?
|
| Fundus Oculi | 1 | 2016 | 5 | 0.040 |
Why?
|
| Retinal Vessels | 1 | 2016 | 24 | 0.040 |
Why?
|
| Capillary Permeability | 1 | 2016 | 30 | 0.040 |
Why?
|
| Protease Inhibitors | 1 | 2016 | 49 | 0.030 |
Why?
|
| Electrochemical Techniques | 1 | 2016 | 22 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2016 | 67 | 0.030 |
Why?
|
| Aspirin | 1 | 1996 | 49 | 0.030 |
Why?
|
| Quantum Theory | 1 | 2016 | 78 | 0.030 |
Why?
|
| Antibody Formation | 1 | 2015 | 74 | 0.030 |
Why?
|
| Immunization | 1 | 2015 | 92 | 0.030 |
Why?
|
| United States | 1 | 2005 | 4223 | 0.030 |
Why?
|
| X-Ray Diffraction | 1 | 2014 | 57 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2016 | 431 | 0.030 |
Why?
|
| Calibration | 1 | 2014 | 56 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2014 | 59 | 0.030 |
Why?
|
| DNA, Circular | 1 | 2013 | 8 | 0.030 |
Why?
|
| Replicon | 1 | 2012 | 8 | 0.030 |
Why?
|
| 5' Untranslated Regions | 1 | 2012 | 18 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2012 | 122 | 0.030 |
Why?
|
| Green Fluorescent Proteins | 1 | 2013 | 208 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 161 | 0.030 |
Why?
|
| Umbilical Veins | 1 | 2011 | 17 | 0.020 |
Why?
|
| Dipeptides | 1 | 2011 | 32 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 935 | 0.020 |
Why?
|
| Rabbits | 1 | 2011 | 283 | 0.020 |
Why?
|
| Aged | 1 | 2021 | 6741 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2011 | 237 | 0.020 |
Why?
|
| Adolescent | 1 | 2019 | 5363 | 0.020 |
Why?
|
| Cell Movement | 1 | 2011 | 571 | 0.020 |
Why?
|